THOMAS JEFFERSON UNIVERSITY

Insurance restrictions force some cancer patients to travel hours for CAR T-cell therapy, impacting treatment access. A study found age, race, income, and proximity to treatment centers significantly affect who receives CAR T. Employers increasingly use Centers of Excellence to manage costs, but this restricts patient options. Despite stringent post-treatment monitoring, a recent study suggests reducing the monitoring period to 2 weeks could improve accessibility.

Jefferson CEO, Dr. Joseph Cacchione, discusses the transformative union with Lehigh Valley Health Network, highlighting advancements in care, technology, and community impact, aiming to improve access and quality of healthcare for the region.

Kineta's abstract on KVA12123 clinical program accepted for poster presentation at SITC 40th Annual Meeting, Nov 6-10, 2024. Jason Henry M.D. to present new clinical data on KVA12123, a VISTA blocking immunotherapy, on Nov 8, 2024.

Dr. William Kevin Kelly discusses AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer, highlighting its mechanism, dosing optimization, and efficacy in heavily pretreated patients. He notes manageable cytokine release syndrome and musculoskeletal side effects, with plans for a phase 3 trial comparing Xaluritamig to standard therapies. The drug shows promising results in late-stage prostate cancer, with durable outcomes and potential to change clinical practice, though further research on optimal sequencing and combination strategies is needed.

Innate Pharma SA will co-host a hybrid scientific symposium on October 3, 2024, with Mount Sinai, featuring key opinion leaders in immunotherapy. The event marks Innate Pharma's 25th anniversary and highlights next-generation immunotherapy discoveries.

A team flagged data-integrity issues in 130 studies by a biomedical researcher, Ahmed Abbas, and colleagues, published between 2014-2023. Concerns include odd statistics, unfeasible results, and duplicated text. Eleven studies have been retracted, impacting clinical practice. Women’s health specialists are developing strategies to prevent questionable data publication.

Ideaya Biosciences announced positive phase 2 data for darovasertib in neoadjuvant uveal melanoma, showing 49% tumor shrinkage and 61% eye preservation. The FDA Type C meeting supported eye preservation and time to vision loss as primary endpoints, paving the way for a potential registrational phase 3 trial.

IDEAYA Biosciences reports positive Phase II data for darovasertib in neoadjuvant uveal melanoma, with 49% of patients showing >30% tumor shrinkage and a favorable adverse event profile. The company plans a Phase III trial with 400 patients, focusing on eye preservation and time to vision loss as primary endpoints.

IDEAYA Biosciences reports positive Phase 2 darovasertib data in neoadjuvant uveal melanoma, with ~49% tumor shrinkage and ~61% eye preservation. A Phase 3 registrational trial is planned following FDA guidance, targeting ~400 patients. Annual incidence of primary UM in North America, Europe, and Australia is ~12k, with no FDA-approved therapies.